Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

August 28, 2022

Study Completion Date

May 28, 2023

Conditions
Acute Stroke
Interventions
DRUG

Glibenclamide

Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.

DRUG

Placebo

Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.

Trial Locations (8)

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

510515

Huadu District People's Hospital of Guangzhou, Guangzhou

570100

Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou

570208

Haikou People's Hospital, Haikou

Unknown

Nanfang Hospital of Southern Medical University, Guangzhou

Heyuan People's Hospital, Heyuan

Maoming People's Hospital, Maoming

Maoming Traditional Chinese Medical Hospital, Maoming

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT03284463 - Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism | Biotech Hunter | Biotech Hunter